期刊
ACTA PHARMACOLOGICA SINICA
卷 41, 期 7, 页码 959-969出版社
NATURE PUBL GROUP
DOI: 10.1038/s41401-020-0415-5
关键词
cancer immunotherapy; dendritic cells; cancer antigens; DC vaccination; mRNA-pulsed DC vaccines; T-cell activation; tumor microenvironment
资金
- National Natural Science Foundation of China [81872821]
- National Key S&T Special Projects [2018ZX09201018-024]
As the most powerful antigen-presenting cell type, dendritic cells (DCs) can induce potent antigen-specific immune responses in vivo, hence becoming optimal cell population for vaccination purposes. DCs can be derived ex vivo in quantity and manipulated extensively to be endowed with adequate immune-stimulating capacity. After pulsing with cancer antigens in various ways, the matured DCs are administrated back into the patient. DCs home to lymphoid organs to present antigens to and activate specific lymphocytes that react to a given cancer. Ex vivo pulsed DC vaccines have been vigorously investigated for decades, registering encouraging results in relevant immunotherapeutic clinical trials, while facing some solid challenges. With more details in DC biology understood, new theory proposed, and novel technology introduced (featuring recently emerged mRNA vaccine technology), it is becoming increasingly likely that ex vivo pulsed DC vaccine will fulfill its potential in cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据